$93.3 Million is the total value of Healthcare Value Capital, LLC's 20 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 90.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $22,353,000 | – | 100,000 | +100.0% | 23.95% | – |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $9,093,000 | -31.5% | 150,000 | -25.0% | 9.74% | -53.7% |
| PFE | Buy | PFIZER INC | $8,120,000 | +37.0% | 250,000 | +42.9% | 8.70% | -7.3% |
| NVLNF | New | NOVELION THERAPEUTICS INC | $7,001,000 | – | 831,440 | +100.0% | 7.50% | – |
| DEPO | DEPOMED INC | $6,307,000 | -27.8% | 350,000 | 0.0% | 6.76% | -51.2% | |
| AMRI | New | ALBANY MOLECULAR RESH INC | $5,673,000 | – | 302,400 | +100.0% | 6.08% | – |
| GILD | Buy | GILEAD SCIENCES INC | $5,371,000 | +171.5% | 75,000 | +200.0% | 5.75% | +83.7% |
| DEPO | New | DEPOMED INCcall | $4,505,000 | – | 250,000 | +100.0% | 4.83% | – |
| GILD | Buy | GILEAD SCIENCES INCcall | $4,297,000 | +55.2% | 60,000 | +71.4% | 4.60% | +4.9% |
| AMGN | New | AMGEN INC | $3,655,000 | – | 25,000 | +100.0% | 3.92% | – |
| AGN | New | ALLERGAN PLC | $3,150,000 | – | 15,000 | +100.0% | 3.38% | – |
| CRY | CRYOLIFE INC | $2,873,000 | +9.0% | 150,000 | 0.0% | 3.08% | -26.3% | |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDadr | $2,719,000 | – | 75,000 | +100.0% | 2.91% | – |
| ARLZ | ARALEZ PHARMACEUTICALS INC | $2,536,000 | -9.1% | 575,000 | 0.0% | 2.72% | -38.5% | |
| BIS | New | PROSHARES TRcall | $1,750,000 | – | 50,000 | +100.0% | 1.88% | – |
| VIXY | New | PROSHARES TR IIcall | $1,595,000 | – | 75,000 | +100.0% | 1.71% | – |
| AMRN | AMARIN CORP PLCspons adr new | $1,386,000 | -3.5% | 450,000 | 0.0% | 1.48% | -34.7% | |
| SNSS | SUNESIS PHARMACEUTICALS INCcall | $543,000 | -17.2% | 150,000 | 0.0% | 0.58% | -44.0% | |
| ZGNX | ZOGENIX INC | $387,000 | +6.3% | 31,850 | 0.0% | 0.42% | -28.1% | |
| FCSC | Sell | FIBROCELL SCIENCE INC | $30,000 | -71.7% | 47,769 | -67.7% | 0.03% | -81.0% |
| APRI | Exit | APRICUS BIOSCIENCES INC | $0 | – | -440,000 | -100.0% | -0.24% | – |
| KITE | Exit | KITE PHARMA INCput | $0 | – | -8,600 | -100.0% | -0.76% | – |
| TWM | Exit | PROSHARES TRultsht russ2000 | $0 | – | -25,000 | -100.0% | -1.14% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -100,000 | -100.0% | -1.45% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS INCput | $0 | – | -75,000 | -100.0% | -2.91% | – |
| ANIP | Exit | ANI PHARMACEUTICALS INCput | $0 | – | -50,000 | -100.0% | -5.26% | – |
| QLTI | Exit | QLT INC | $0 | – | -2,157,200 | -100.0% | -7.04% | – |
| Exit | ALBANY MOLECULAR RESH INC | $0 | – | -302,400 | -100.0% | -7.91% | – | |
| DGX | Exit | QUEST DIAGNOSTICS INC | $0 | – | -66,208 | -100.0% | -8.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-10
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC | 20 | Q3 2021 | 31.3% |
| GLAXOSMITHKLINE PLC | 20 | Q3 2021 | 16.1% |
| PFIZER INC | 19 | Q3 2021 | 17.9% |
| TYME TECHNOLOGIES INC | 17 | Q3 2021 | 40.3% |
| ASTRAZENECA PLC | 14 | Q3 2021 | 12.9% |
| QUEST DIAGNOSTICS INC | 14 | Q3 2016 | 9.5% |
| CRYOLIFE INC | 13 | Q1 2017 | 6.6% |
| ANTARES PHARMA INC | 13 | Q3 2021 | 6.7% |
| AMARIN CORP PLC | 13 | Q3 2021 | 4.9% |
| CYTOKINETICS INC | 13 | Q3 2016 | 1.7% |
View Healthcare Value Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NOVELION THERAPEUTICS INC. | September 20, 2019 | 1,400,000 | 7.4% |
View Healthcare Value Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| SC 13D/A | 2019-09-20 |
View Healthcare Value Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.